Cyclic EGFR Peptides That Trigger Receptor Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current EGFR inhibitors, such as monoclonal antibodies and tyrosine kinase inhibitors, face limitations in efficacy due to genetic instability and resistance mechanisms, particularly in cancers with KRAS mutations, necessitating the development of alternative EGFR inhibitors that can overcome these drawbacks.
Innovation Solution
Development of cyclic peptides that bind to the extracellular domain of EGFR, initiating non-clathrin mediated endocytosis and lysosomal degradation, providing potent and long-lasting inhibitory activity against EGFR expression and signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies or tyrosine kinase inhibitors are used to inhibit EGFR, then EGFR activity is blocked, but resistance develops due to genetic instability and mutation
Solution Approach 1:
The invention extracts the inhibitory function from traditional antibody or TKI mechanisms and implements it through cyclic peptides that bind to the extracellular domain of EGFR, initiating non-clathrin mediated endocytosis and lysosomal degradation of the receptor, thereby removing EGFR from the cell surface and preventing resistance development
Solution Approach 2:
The invention changes the mechanism parameter from blocking ligand binding or inhibiting kinase activity to inducing receptor internalization and degradation, fundamentally altering how EGFR inhibition is achieved and preventing adaptive resistance
2Reliability
If tyrosine kinase inhibitors target the intracellular kinase domain, then EGFR signaling is inhibited, but the genetically unstable region is targeted leading to resistance
Solution Approach 1:
The invention extracts the target from the intracellular kinase domain to the extracellular ligand-binding domain, avoiding the genetically unstable regions prone to mutation while maintaining effective EGFR inhibition through cyclic peptide binding and induced receptor degradation
Solution Approach 2:
Instead of targeting the intracellular kinase domain as conventional TKIs do, the invention inverts the approach by targeting the extracellular domain and inducing receptor internalization, thereby avoiding the genetically unstable regions that lead to resistance
3Reliability
If cetuximab is used to block ligand activation, then EGFR signaling is inhibited, but de novo resistance arises from KRAS, BRAF and NRAS mutations
Solution Approach 1:
The invention extracts the mechanism from simple ligand binding blockade to induction of non-clathrin mediated endocytosis and lysosomal degradation, thereby achieving more complete and durable EGFR inhibition that overcomes resistance to cetuximab and other conventional therapies
Solution Approach 2:
The cyclic peptides combine multiple functional elements: extracellular domain binding, induction of non-clathrin mediated endocytosis, and targeting for lysosomal degradation, creating a composite inhibitory mechanism that is more effective and durable than single-mechanism inhibitors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cyclic peptides effectively inhibit EGFR activity, promote internalization and lysosomal degradation, and reduce cancer cell viability across various cancer types, including those with KRAS mutations, offering a more durable therapeutic approach.
Implementation Method 1
bind to the extracellular domain of EGFR and initiate non-clathrin mediated endocytosis (non-CME) and lysosomal degradation of EGFR protein
Implementation Method 2
initiate non-clathrin mediated endocytosis (non-CME) and lysosomal degradation of EGFR protein
Data Source
AI summary
The present disclosure generally relates to epidermal growth factor receptor (EGFR) inhibitors and methods of treating EGFR-dependent or associated diseases, disorders or conditions, such as cancer.